Gilead Sciences Inc.

Pharmaceuticals
United States
Earnings Per Share Growth (%)62.04%
Cost of Goods Sold (US$ Millions)$4,006
Current Liabilities (US$ Millions)$9,891
Total Assets (US$ Millions)$24,763
Long Term Debt$21,195
Return on Equity117.39%
Revenue (US$ Millions)$32,639
Total Company Assets$51,839
Revenue Growth (%)31.13%
Net Income (US$ Millions)$18,108
Earnings Per Share (US$)$62.04
Total Equity (US$ Millions)$18,534
Profit Margin (%)55.48%
Debt To Equity Ratio (%)1.14%
Inventory Turnover$1,955